论文部分内容阅读
FDA批准第一种用于治疗慢性铁过量的口服药物 2005年11月9日,美国FDA宣布批准Novartis(诺华)公司的口服铁螯合剂Exjade(deferasirox) 用于治疗成人及两岁以上儿童由于多次输血引起的慢性铁过量。 Exjade是第一种也是唯一一种用于治疗此类疾病的口服药物。在为期48周的临床试验中发现,对于 持续接受输血的成人及儿童患者,该药均可降低其肝脏铁的储积量。 铁过量可损伤心脏和肝脏,过去对此类疾病的治疗,常需要长达8-12 h的注射给药,每周要接受5-7 次注射。给药的不便使很多患者最后停止或避免接受铁螯合剂注射治疗,而体内铁过量又可能导致一系 列的并发症。口服治疗不仅可以提高患者的依从性,并且可减轻铁过量的并发症。
FDA Approves First Oral Medication for the Treatment of Chronic Iron Exodus FDA announced on November 9, 2005 that it has approved the Novartis oral iron chelator Exjade (deferasirox) for the treatment of adults and children over the age of two due to more Chronic iron overload caused by transfusion. Exjade is the first and only oral medication for the treatment of such diseases. In a 48-week clinical trial, it was found that this drug reduces the amount of iron stored in the liver in both adult and pediatric patients who continue to receive blood transfusions. Excess iron can damage the heart and liver. In the past, the treatment of such diseases often required up to 8-12 hours of injection and 5-7 times weekly. The inconvenience of dosing resulted in the last stop or avoidance of iron chelator injections in many patients, which in turn can lead to a series of complications. Oral therapy not only improves patient compliance, but also reduces the complications of iron overload.